Release Date: December 10, 2022
Expiration Date: January 1, 2023
Activity Overview
This educational activity is an archive of the live virtual presentation held on December 9, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This activity is intended for medical oncologists, hematologists, and other oncology healthcare professionals interested in the latest advances in the treatment of patients with non-Hodgkin lymphoma. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with non-Hodgkin lymphoma are also invited to attend.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe diagnostic and prognostic biomarkers that guide treatment planning in indolent and aggressive B-cell malignancies
- Integrate safety and efficacy data for emerging treatment options, including chemotherapy-free regimens, to clinical scenarios in patients with B-cell NHL
- Identify strategies to mitigate, monitor, and manage adverse events associated with therapeutic regimens used in the treatment of patients with B-cell NHL
- Assess recently reported and ongoing clinical trials of novel agents and therapeutic combinations for patients with indolent and aggressive B-cell malignancies
Andre H. Goy, MD
Physician-in-Chief
Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer
John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman, Oncology - Hackensack Meridian School of Medicine
Professor of Medicine - Georgetown University
Hackensack, NJ
Disclosures: Grant/Research Support: PI (Reserach to insitution) -Acerta, AstraZenca, Bristol Meyers, Celgene, Genentech, Genentech-Hoffman La Roche, Hoffman La Roche,Infinity, Janseen, Karyopharm, Kite pharma, MorphoSys, Pharmacyclics, Seattle Genetics. Verastem; Stock/Shareholder: COTA, Alloplex, Resilience, Genomic Testing Cooperative; Other: Advisory/ Board-Kite, Gilead, Pharmacyclics, Elsevier's PracticeUpdate Oncology, Janseen Biotech; Board of Directors- COTA, Resilience, Genomic Testing Cooperative; Consulting Faculty- Roswell Park, Michael J Hennessey Associates, INC, Physcians Education Resource, LLC; Scientific Advisory Board- Alloplex, BMS, Vincerx; Steering Committee- Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.
Lorenzo Falchi, MD
Assistant Attending Physician
Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant/Research Support: Genentech/Roche, Genmab; Consultant: Genentech/Roche, Genmab, Abbvie, ADC Therapeutics, AstraZeneca; Other Support: CME Presentation: Projects in Knowledge (Kaplan); Journal Editor: Taylor Francis.
Lori A. Leslie, MD
Director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs
John Theurer Cancer Center
Associate Professor
Hackensack Meridian School of Medicine
Hackensack University Medical Center
Hackensack, NJ
Disclosures: Consultant: Beigene, , SeaGen, Abbvie, Epizyme, Janssen, Pharmacyclics, Kite/Gilead, AstraZeneca, Merck, Celgene, TG therapeutics, Lily; Speakers’ Bureau: SeaGen, EliLilly, KitePharma, BeiGene, Pharmacyclics/Janssen, AstraZeneca, Epizyme, TG therapeutics, Karyopharm.
Michael L. Wang, MD
Puddin Clarke Endowed Professor
Department of Lymphoma and Myeloma
University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genentech, Innocare, Janssen, Juno, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, VelosBio; Consultant: AstraZeneca, Bayer Healthcare, BeiGene, CSTone, DTRM Biopharma (Cayman) Limited, Epizyme, Genentech, InnoCare, Janssen, Juno, Kite Pharma, Loxo Oncology, Miltenyi Biomedicine, GmbH, Oncternal, Pharmacyclics, VelosBio; Speakers’ Bureau: Acerta Pharma, Anticancer Association, AstraZeneca, BeiGene, CAHON, Chinese Medical Association, Clinical Care Options, Dava Oncology, Epizyme, Hebei Cancer Prevention Federation, Imedex, Janssen, Kite Pharma, Miltenyi Biomedicine GmbH, Moffit Cancer Center, Mumbai Hematology Group, Newbridge Pharma.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
